Dr. Bernard Thébaud and colleagues have received a $638,000 grant from the Stem Cell Network with in-kind matching funds from MDTB Cells GmbH to conduct a phase I clinical trial of umbilical cord cell therapy for premature babies. This trial aims to determine if this therapy is safe and feasible for these babies and if so, the findings from this phase I study will support a larger Canadian phase II clinical trial to test if the therapy can effectively treat BPD.
